Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 11Waldenstrom Macroglobulinemia 4Recurrence 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma 4Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3Lymphoma, B-Cell 3Leukemia 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Acute 2Burkitt Lymphoma 2Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1Neoplasms, Plasma Cell 1Multi-centric Castleman's Disease 1Mastocytosis, Systemic 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Immunoblastic 1Leukemia, Mast-Cell 1Leukemia, Lymphoid 1Leukemia, Hairy Cell 1Intraocular Lymphoma 1Hypergammaglobulinemia 1Hematologic Neoplasms 1Hematologic Diseases 1

Interventions

Dexamethasone 2Calcium Dobesilate 2Bortezomib 2pomalidomide 1ibrutinib 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1atezolizumab 1Transplantation, Autologous 1Melphalan 1Lenalidomide 1Gene Expression Profiling 1Fatty Acids, Omega-3 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Smoldering Multiple Myeloma × ibrutinib × Clear all
NCT02943473 2020-12-16

Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients

Icahn School of Medicine at Mount Sinai

Phase 2 Terminated
9 enrolled 6 charts
Plasma cell

Smoldering Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡